Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02098109 · ClinicalTrials.gov registry record · Phase 2
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02098109 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 100 participants.
The verdict
NCT02098109, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
Interventions
- PROCEDURE Apheresis
- DRUG Plerixafor
- DRUG Filgrastim
- PROCEDURE Stem Cell Transplant
- DRUG XM02 Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-08-20 |
| Est. Completion | 2016-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02098109
The ClinicalTrials.gov registry entry for NCT02098109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apheresis is the first listed.
NCT02098109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02098109 about?
NCT02098109 is a clinical study titled "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma". This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
What is the current status of trial NCT02098109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-08-20. Estimated completion is 2016-09-18.
What interventions are being tested in trial NCT02098109?
The interventions under investigation include: Apheresis (PROCEDURE), Plerixafor (DRUG), Filgrastim (DRUG), Stem Cell Transplant (PROCEDURE), XM02 Filgrastim (DRUG).
Who is sponsoring clinical trial NCT02098109?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.